Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Barclays PLC

Barclays PLC boosted its stake in Revolution Medicines, Inc. (NASDAQ:RVMDFree Report) by 22.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 228,661 shares of the company’s stock after buying an additional 42,336 shares during the period. Barclays PLC owned 0.21% of Revolution Medicines worth $6,329,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. MetLife Investment Management LLC lifted its stake in shares of Revolution Medicines by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 34,256 shares of the company’s stock worth $874,000 after acquiring an additional 12,643 shares during the period. Dimensional Fund Advisors LP lifted its stake in Revolution Medicines by 165.5% during the first quarter. Dimensional Fund Advisors LP now owns 478,776 shares of the company’s stock valued at $12,214,000 after buying an additional 298,436 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Revolution Medicines by 3.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 444,212 shares of the company’s stock worth $11,332,000 after buying an additional 13,134 shares during the period. Northern Trust Corp increased its position in shares of Revolution Medicines by 12.3% in the first quarter. Northern Trust Corp now owns 629,849 shares of the company’s stock worth $16,067,000 after acquiring an additional 68,794 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Revolution Medicines by 3.2% during the first quarter. State Street Corp now owns 2,843,477 shares of the company’s stock valued at $72,537,000 after acquiring an additional 88,844 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on RVMD shares. Oppenheimer lifted their price objective on shares of Revolution Medicines from $40.00 to $43.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Wedbush assumed coverage on Revolution Medicines in a research report on Thursday, January 4th. They set an “outperform” rating and a $41.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of Revolution Medicines in a research report on Tuesday, November 7th. Bank of America upgraded shares of Revolution Medicines from a “neutral” rating to a “buy” rating and raised their price target for the stock from $31.00 to $34.00 in a report on Friday, January 5th. Finally, JPMorgan Chase & Co. cut their price objective on Revolution Medicines from $47.00 to $39.00 and set an “overweight” rating for the company in a report on Tuesday, November 7th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.82.

Get Our Latest Stock Analysis on RVMD

Revolution Medicines Price Performance

Shares of NASDAQ RVMD opened at $30.38 on Friday. The business’s 50-day simple moving average is $27.38 and its 200-day simple moving average is $27.17. Revolution Medicines, Inc. has a 52 week low of $15.44 and a 52 week high of $35.60.

Revolution Medicines (NASDAQ:RVMDGet Free Report) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.02. Revolution Medicines had a negative return on equity of 38.92% and a negative net margin of 1,003.36%. During the same quarter in the prior year, the firm earned ($0.87) EPS. Equities analysts forecast that Revolution Medicines, Inc. will post -3.47 earnings per share for the current year.

Insider Buying and Selling

In other news, General Counsel Jeff Cislini sold 1,500 shares of Revolution Medicines stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $21.70, for a total value of $32,550.00. Following the transaction, the general counsel now directly owns 38,513 shares in the company, valued at $835,732.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Margaret A. Horn sold 2,993 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $25.90, for a total value of $77,518.70. Following the completion of the sale, the chief operating officer now owns 101,467 shares in the company, valued at $2,627,995.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Jeff Cislini sold 1,500 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $21.70, for a total value of $32,550.00. Following the transaction, the general counsel now owns 38,513 shares in the company, valued at $835,732.10. The disclosure for this sale can be found here. Insiders have sold 58,833 shares of company stock worth $1,636,872 in the last quarter. 8.50% of the stock is currently owned by company insiders.

Revolution Medicines Company Profile

(Free Report)

Revolution Medicines, Inc, a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.

Read More

Institutional Ownership by Quarter for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.